Biomarkers to predict the clinical outcome of hepatitis delta
A Wranke, BC Serrano, S Ernst, B Heidrich, J Kirschner, B Bremer, S Hardtke, M Cornberg, A Koch, MP Manns, CS Falk, H Wedemeyer · Zeitschrift für Gastroenterologie · 2015 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: Hepatitis delta is the most severe form of viral hepatitis. Pegylated interferon alpha is effective in only 25 – 30% of patients and associated with frequent side effects. Thus, it is crucial to identify patients with benign courses of liver disease who may not require treatment. We recently introduced a baseline-event-anticipation (BEA)-Score for hepatitis delta considering thrombocytes, bilirubin, INR, age, sex and country of origin as factors being associated with the development of clinical endpoints. The aim of this study was to improve the BEA-Score with easy to measure biomarkers. Methods: We…
